Genomic rearrangement of TMPRSS2 fusions with oncogenic ETS factors: Evidence of epigenetic programming of potential therapeutic significance in prostate cancer

被引：0
|
作者：
Gupta, Santosh K. [1 ]
Wol, Maija [1 ]
Ljlin, Ktsitiina [1 ]
Nees, Matthias [1 ]
Kallioniemi, Olli [1 ]
机构：
[1] Univ Turku, SF-20500 Turku, Finland
来源：
CELLULAR ONCOLOGY | 2008年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：241 / 241
页数：1
相关论文
共 50 条
  • [21] The Discovery of Common Recurrent Transmembrane Protease Serine 2 (TMPRSS2)-Erythroblastosis Virus E26 Transforming Sequence (ETS) Gene Fusions in Prostate Cancer Significance and Clinical Implications
    Shah, Rajal B.
    Chinnaiyan, Arul M.
    ADVANCES IN ANATOMIC PATHOLOGY, 2009, 16 (03) : 145 - 153
  • [22] TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer
    Tomlins, SA
    Mehra, R
    Rhodes, DR
    Smith, LR
    Roulston, D
    Helgesson, BE
    Cao, XH
    Wei, JT
    Rubin, MA
    Shah, RB
    Chinnaiyan, AM
    CANCER RESEARCH, 2006, 66 (07) : 3396 - 3400
  • [23] Can fusion of TMPRSS2 and ETS genes explain androgen-dependent prostate cancer growth?
    Hermans, K.
    Van Marion, R.
    Van Dekken, H.
    Jenster, G.
    Van Weerden, W.
    Trapman, J.
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (14) : 807 - 807
  • [24] Molecular signature and clinical implications of TMPRSS2 and ETS transcription family genes fusions in a surgical cohort of American men treated for clinically localized prostate cancer
    Mehra, R.
    Tomlins, S.
    Shen, R.
    Wang, L.
    Wei, J.
    Pienta, K.
    Ghosh, D.
    Rubin, M. A.
    Chinniayan, A.
    Shah, R. B.
    MODERN PATHOLOGY, 2007, 20 : 163A - 163A
  • [25] Molecular signature and clinical implications of TMPRSS2 and ETS transcription family genes fusions in a surgical cohort of American men treated for clinically localized prostate cancer
    Mehra, R.
    Tomins, S.
    Shen, R.
    Wang, L.
    Pienta, K.
    Ghosh, D.
    Rubin, M. A.
    Chinniayan, A.
    Shah, R. B.
    LABORATORY INVESTIGATION, 2007, 87 : 163A - 163A
  • [26] Androgen receptor CAG repeat length and TMPRSS2: ETS prostate cancer risk: results from the Prostate Cancer Prevention Trial
    Price, Douglas K.
    Chau, Cindy H.
    Figg, William D.
    Till, Catherine A.
    Goodman, Phyllis J.
    Cho, Yonggon
    Garcia, Marileila
    Reichardt, Juergen
    Tangen, Catherine M.
    Leach, Robin J.
    van Bokhoven, Adrie
    Kristal, Alan R.
    Thompson, Ian M.
    Lucia, M. Scott
    CANCER RESEARCH, 2014, 74 (19)
  • [27] Androgen Receptor CAG Repeat Length and TMPRSS2:ETS Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial
    Figg, William D.
    Chau, Cindy H.
    Price, Douglas K.
    Till, Cathee
    Goodman, Phyllis J.
    Cho, Yonggon
    Varella-Garcia, Marileila
    Reichardt, Juergen K. V.
    Tangen, Catherine M.
    Leach, Robin J.
    van Bokhoven, Adrie
    Thompson, Ian M.
    Lucia, M. Scott
    UROLOGY, 2014, 84 (01) : 127 - 131
  • [28] Feasibility of RNA sequencing to detect TMPRSS2: ERG fusions following laser capture microdissection of prostate cancer
    Kim, Won
    Foye, Adam
    Bengtsson, Henrik
    Kim, Hyunsung John
    Taylor, Barry S.
    Pourmand, Nader
    Febbo, Phillip G.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [29] Etiology of prostate cancer with the TMPRSS2:ERG fusion: A systematic review of risk factors
    Mcgrath, Colleen B.
    Shreves, Alaina H.
    Shanahan, Megan R.
    Guard, Hannah E.
    Nhliziyo, Manelisi V.
    Pernar, Claire H.
    Penney, Kathryn L.
    Lotan, Tamara L.
    Fiorentino, Michelangelo
    Mucci, Lorelei A.
    Stopsack, Konrad H.
    INTERNATIONAL JOURNAL OF CANCER, 2024,
  • [30] TMPRSS2, a serine protease highly expressed in prostate cancer: A potential target for therapy
    True, LD
    Matsumura, M
    Moore, S
    Morrison, M
    Henneberg, R
    Nelson, PS
    LABORATORY INVESTIGATION, 2003, 83 (01) : 174A - 174A
12345